Presentation is loading. Please wait.

Presentation is loading. Please wait.

Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G

Published byLeony Pranata Modified over 6 years ago

Similar presentations

Presentation on theme: "Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G"— Presentation transcript:

1 Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? 
Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G. Nicholson, DM, FRCPath, Yasushi Yatabe, MD, PhD, Ignacio I. Wistuba, MD, PhD, Fred R. Hirsch, MD, PhD  Journal of Thoracic Oncology  Volume 10, Issue 7, Pages (July 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Programmed death receptor-1 with its ligand (PDL-1) immunostaining performed using the E1LN3N clone anti-PD-L1 from Cell Signaling Technology (Boston) with standard detection techniques. A, Squamous cell carcinoma showing a strong, uniform positive reaction in tumor cells. B, Despite being negative in tumor cells in the center of the image, there is a positive reaction in macrophages and other immune cells in the tumor stroma. C, Most alveolar macrophages are positive for PD-L1. D, This adenocarcinoma is negative for PD-L1. It should be noted that this immunohistochemistry clone was not used for PD-L1 detection in any of the trials discussed in this review. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G"

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project  Fred R. Hirsch, MD, PhD,

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project  Fred R. Hirsch, MD, PhD,
Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD 

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD 
David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart  William D. Travis, MD, Elisabeth Brambilla,

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart  William D. Travis, MD, Elisabeth Brambilla,
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Ugonna N. Ihekweazu, BS, William D. Travis, MD, Raja M. Flores, MD 

Ugonna N. Ihekweazu, BS, William D. Travis, MD, Raja M. Flores, MD 
The 2015 World Health Organization Classification of Lung Tumors

The 2015 World Health Organization Classification of Lung Tumors
Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer  Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,

Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer  Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD 

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD 
David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project  Fred R. Hirsch, MD, PhD,

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project  Fred R. Hirsch, MD, PhD,
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Similar presentations

Ads by Google